omniture
logo
Search
CUROCELL INC
Media Room

Latest News

rss

Curocell Completes Korea's First Phase 2 Clinical Trial for Next-Generation CAR-T

* Anbal-cel targeting DLBCL completes phase 2 trial * Anticipation growing over Korea's first CAR...

2023-11-01 16:23 1679

Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023

* 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg ...

2023-06-20 08:01 1125
Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023

Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform

-  82% ORR (9 of 11 patients) and 82% (9 of 11 patients) CR rate documented after  anbal-cel treatm...

2022-06-13 19:00 1908
Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform

Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility'

DAEJEON, South Korea, Dec. 23, 2021 Curocell, currently on PhaseⅠCAR-T Therapy clinical trial withC...

2021-12-23 20:00 2199
Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility'

Curocell announces Korean FDA clearance of the IND for CRC01, a first in kind immune checkpoint receptors downregulated CD19 CAR-T therapy

DAEJEON, South Korea, Feb. 22, 2021 /PRNewswire/ -- Curocell, Inc., a clinical-stage biotech develo...

2021-02-22 22:00 1383